Breaking News

Japan July Industrial Output Rises 0.2% Against Estimated 1% Gain
Tweet TWEET

Clinical Study Updates, Financial Results, Conference Schedules, and Securities Offerings - Research Report on Novo Nordisk, The

     Clinical Study Updates, Financial Results, Conference Schedules, and
Securities Offerings - Research Report on Novo Nordisk, The Cooper Companies,
                        Parexel, Oculus, and Thoratec

PR Newswire

NEW YORK, December 10, 2013

NEW YORK, December 10, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Novo
Nordisk A/S (NYSE: NVO), The Cooper Companies Inc. (NYSE: COO), PAREXEL
International Corporation (NASDAQ: PRXL), Oculus Innovative Sciences, Inc.
(NASDAQ: OCLS) and Thoratec Corp. (NASDAQ: THOR). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Novo Nordisk A/S Research Report

On December 3, 2013, Novo Nordisk A/S (Novo Nordisk) announced that a new
phase 3 data from the investigational therapy IDegLira were presented at the
World Diabetes Congress of the International Diabetes Federation. According to
the Company, IDegLira is the first-ever once-daily, single administration
combination of a long-acting basal insulin and glucagon-like peptide 1 (GLP-1)
analogue being developed by Novo Nordisk. The Company informed that the DUAL™
II trial shows that in comparison with insulin degludec, IDegLira achieved
superior control of blood sugar levels (HbA1c). Also, improved fasting and
postprandial plasma glucose levels were seen with IDegLira throughout the day
and across meals, while providing significant weight loss for adults with type
2 diabetes uncontrolled on basal insulin. The Full Research Report on Novo
Nordisk A/S - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/fee1_NVO

--

The Cooper Companies Inc. Research Report

On December 5, 2013, The Cooper Companies, Inc. (Cooper) reported its Q4 FY
2013 and full-year FY 2013 financial results (period ended October 21, 2013).
During the quarter, the Company reported revenue growth of 3.9% YoY to $411.9
million, while diluted EPS declined 21.2% YoY to $1.15. For full-year FY 2013,
revenues came in at $1.6 billion, representing a growth of 9.9% YoY, and
diluted EPS came in at $5.96, reflecting an increase of 18.0% YoY. Commenting
on the results, Robert S. Weiss, Cooper's President and CEO said, "We are
proud of our many accomplishments throughout the year including CooperVision's
success with its Biofinity® family of products and launch of MyDay™ along with
CooperSurgical's success with its fertility franchise. As we enter fiscal
2014, we remain encouraged by our business trends and believe we are well
positioned to deliver strong operating results." The Full Research Report on
The Cooper Companies Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/9cde_COO

--

PAREXEL International Corporation Research Report

Parexel International Corp. (Parexel) posted on their events web page that the
Company will be participating in the upcoming JPMorgan Healthcare Conference,
to be held on January 15, 2014, Wednesday at 7:30 a.m. PT. Parexel posted that
the event will be held in San Francisco, California, US. The Full Research
Report on PAREXEL International Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/067b_PRXL

--

Oculus Innovative Sciences, Inc. Research Report

On December 4, 2013, Oculus Innovative Sciences, Inc. (Oculus) announced an
offering to sell securities to select accredited investors for aggregate gross
proceeds of $2.2 million. Oculus stated that it intends to use the net
proceeds from the offering for working capital and general corporate purposes.
The securities in the offering include 550,000 shares of Oculus common stock
at a price of $4.00 per share with no warrant coverage. The Company expects
the offering to close on or about December 9, 2013, subject to satisfaction of
customary closing conditions. The Full Research Report on Oculus Innovative
Sciences, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/a3ee_OCLS

--

Thoratec Corp. Research Report

Thoratec Corp. (Thoratec) posted on their events web page that the Company
will be presenting at the upcoming Oppenheimer Healthcare Conference. As per
the post, the presentation will be held on December 10, 2013 at 2:10 p.m. ET
and will be broadcast live over the internet. The Full Research Report on
Thoratec Corp. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/1bee_THOR

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.